Related Experiment Videos

Methicillin resistance in Staphylococcus aureus: mechanisms and modulation

Paul D Stapleton1, Peter W Taylor

  • 1School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX. paul.stapleton@ulsop.ac.uk

Science Progress
|April 24, 2002
PubMed

Insights

Methicillin-resistant Staphylococcus aureus (MRSA) develops resistance via PBP2a. New compounds like epicatechin gallate and corilagin show promise for combating MRSA infections.

Area of Science:

  • Microbiology
  • Medicinal Chemistry

Background:

  • Staphylococcus aureus is a significant pathogen in healthcare and community settings.
  • Methicillin resistance in S. aureus is primarily mediated by the acquisition of PBP2a, a methicillin-resistant penicillin-binding protein.
  • MRSA strains often exhibit multi-drug resistance, limiting therapeutic options.

Purpose of the Study:

  • To explore the mechanisms of methicillin resistance in Staphylococcus aureus.
  • To identify novel therapeutic targets and lead compounds for combating MRSA.

Main Methods:

  • Investigated the role of penicillin-binding proteins (PBPs) in peptidoglycan synthesis.
  • Examined the function of PBP2a in conferring methicillin resistance.
  • Identified accessory factors, such as Fem factors, influencing resistance levels.
  • Evaluated natural compounds like epicatechin gallate and corilagin for their potential to modulate resistance.

Main Results:

  • PBP2a confers resistance to methicillin by performing essential cell wall synthesis functions.
  • Accessory factors, including Fem factors, modulate the degree of methicillin resistance.
  • Epicatechin gallate and corilagin demonstrate potential as modulators of methicillin resistance.

Conclusions:

  • Understanding PBP2a and accessory factors is crucial for developing new anti-MRSA strategies.
  • Natural compounds like epicatechin gallate and corilagin represent promising starting points for novel MRSA inhibitor development.

Related Concept Videos